Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of AR120343A1publicationCriticalpatent/AR120343A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Reivindicación 1: Una composición farmacéutica que comprende crizanlizumab que tiene las secuencias de aminoácidos de cadena ligera y cadena pesada en la SEQ ID Nº 10 y la SEQ ID Nº 9 respectivamente, y una variante de crizanlizumab (iso-crizanlizumab), en la cual el aminoácido ácido aspártico en la posición 32 de la SEQ ID Nº 10 se cambia a ácido iso-aspártico.Claim 1: A pharmaceutical composition comprising crizanlizumab having the light chain and heavy chain amino acid sequences in SEQ ID No. 10 and SEQ ID No. 9 respectively, and a variant of crizanlizumab (iso-crizanlizumab), in which the amino acid aspartic acid at position 32 of SEQ ID NO:10 is changed to iso-aspartic acid.